A Study of QLS31905 in Patients With Advanced Solid Tumors

Q

Qilu Pharmaceutical

Status and phase

Enrolling
Phase 1

Conditions

Advanced Solid Tumors

Treatments

Drug: QLS31905

Study type

Interventional

Funder types

Industry

Identifiers

NCT05278832
QLS31905-101

Details and patient eligibility

About

This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.

Enrollment

104 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Written informed consent.
  2. ≥18 years.
  3. Female or male.
  4. ECOG performance status score 0 or 1.
  5. Histologically or cytologically confirmed diagnosis of advanced solid tumors.
  6. Adequate haematological, hepatic and renal function.

Exclusion criteria

  1. Any anticancer therapy or immunotherapy within 4 weeks prior to the start of study treatment.
  2. Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.
  3. Patients with a history of monoclonal antibody allergic reaction.
  4. Known human immunodeficiency virus infection or known symptomatic hepatitis.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

104 participants in 1 patient group

QLS31905
Experimental group
Description:
QLS31905 injection
Treatment:
Drug: QLS31905

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems